In colorectal cancer, ERBB2 amplification occurs in 5% of RAS wild-type metastatic tumors.1 In the pivotal HERACLES-A trial, chemorefractory patients with ERBB2 (formerly HER2)-positive metastatic colorectal cancer (mCRC) were treated with the combination of trastuzumab and lapatinib,2 demonstrating the proof of concept that the dual ERBB2 blockade previously found actionable in preclinical models3 could be successfully translated to the clinic with remarkable clinical benefit. We also reported that ERBB2 copy number in plasma was associated with that detected in tumor tissue, identified a cutoff value associated with clinical response,4 and studied acquired resistance on therapeutic ERBB2 blockade by longitudinal monitoring of circulating tumor DNA. Along this line, we documented that the onset of resistance was associated with emerging KRAS variant clones, BRAF amplification, and other molecular alterations already known in breast cancer, such as those of ERBB2, EGFR, PIK3CA, and PTEN.5
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sartore-Bianchi A, Lonardi S, Aglietta M, et al. Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. JAMA Oncol. Published online April 23, 2020. doi:10.1001/jamaoncol.2020.0571
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: